1. Prospective evAluatIon foR inhalation devices in Greek patients with COPD and asthma: The PAIR study
- Author
-
Theodoros Karampitsakos, Georgios Hillas, Eleftherios Zervas, Petros Bakakos, Grigorios Stratakos, Katerina Dimakou, Efrosyni Manali, Demosthenes Bouros, Spyridon Papiris, Argyrios Tzouvelekis, Vasilios Adamidis, Helen Adamou, Xenophon Agelidis, Konstantinos Albantakis, Aikaterini Anaplioti, Christos Babalis, George Balasoulis, Konstantinos Christou, Christina Filippidou, Emmanuel Fothiantakis, Anna Gavriilidou, Hypakoe Goulia, Konstantina Houliara, Elias Kainis, Paschalis Kakavelas, Dionysia Kalampoka, George Kalfountzos, Savvas Kammenidis, Konstantinos Karkanis, Eugenia Karyanou, Maria Katertzi, Antonios Kopanakis, Georgia Kotantoula, Adamantia Liapikou, Nikolaos Manolakoglou, Konstantinos Marosis, Demetrios Michailidou, Peter Oikonomides, Anastasios Palamidas, Athanasios Papandreou, Athanasia Pataka, Athanasios Pitenis, Konstantinos Porpodis, Andreas Stratis, Chrysavgi Terovitou, Evangelia Trikrika, Pashalia Tsiaga, Theodora Tsiounta, Athina Vlachou, and Dimitrios Zois
- Subjects
Adult ,Male ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Intraclass correlation ,Pulmonary disease ,Prospective evaluation ,Pulmonary Disease, Chronic Obstructive ,Drug Delivery Systems ,Surveys and Questionnaires ,Internal medicine ,Administration, Inhalation ,Humans ,Medicine ,Pharmacology (medical) ,Anti-Asthmatic Agents ,Prospective Studies ,Lung ,Aged ,Asthma ,Aged, 80 and over ,COPD ,Greece ,business.industry ,Inhaler ,Biochemistry (medical) ,Inhalation Devices ,Dry Powder Inhalers ,Equipment Design ,Middle Aged ,medicine.disease ,Dry-powder inhaler ,Patient Satisfaction ,Female ,business - Abstract
Chronic obstructive pulmonary disease (COPD) and asthma remain a major health burden. Adherence to inhaled therapy is critical in order to optimize treatment effectiveness. Properly designed questionnaires can assess patients' satisfaction with their inhaler devices.A total of 766 patients with COPD, asthma or Asthma-COPD Overlap (ACO) were initially enrolled. During their first visit, patients were classified into three groups (Diskus™, Elpenhaler®, Turbuhaler®). Patients completed the FSI-10 questionnaire on Day 0 and Day 60. Test-retest reliability was evaluated.A total of 705 patients completed the study. FSI-10 questionnaire had good test-retest reliability (Total Intraclass Correlation Coefficient: 0.86). All dry powder inhaler (DPIs) yielded satisfactory results. Median score of FSI-10 questionnaire in first visit (FSI-10-I) was significantly higher for patients receiving Elpenhaler® (45, 95% CI: 44 to 46) than patients receiving Diskus™ (42, 95% CI: 41 to 43) and Turbuhaler® (42, 95% CI: 41 to 43) (p 0.001). Accordingly, median score of FSI-10 questionnaire in the final visit (FSI-10-II) was significantly higher for patients receiving Elpenhaler® (46, 95% CI: 45 to 47) than patients receiving Diskus™ (42, 95% CI: 41 to 43) and Turbuhaler® (43, 95% CI: 42 to 44) (p 0.001).FSI-10 questionnaire had good test-retest reliability and thus can be used in the follow-up of patients with COPD, asthma and ACO. All DPIs were highly acceptable among all study groups. Elpenhaler® achieved significantly higher ratings than Diskus™ and Turbuhaler® in FSI-10 score and presented higher preference among patients with obstructive lung diseases.
- Published
- 2020